NEWS: Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Learn More

Decoding Biology To Radically Improve Lives.

We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical
company.

Relatable and scalable data is one of Recursion’s key differentiators

>50
petabytes

of proprietary  biological, chemical, & patient-centric data

Up to 2.2M
/week

wet lab experiment profiling genes and compounds

Top

500

supercomputer BioHive-1 across any industry

>50 cell types

produced at scale, including >1T hiPSC-derived neuronal cells

>6

trillion

gene and compound relationships profiled in our Maps

Read about our science

Synchronized combination of hardware, software, and data to industrialize drug discovery

Learn about the Recursion OS

Our pipeline reflects the scale and breadth of our approach

Our existing partnerships represent some of the most significant collaborations in TechBio.

Partnering with Recursion
© 2024 Recursion. All rights reserved.
NEWS: Recursion appoints Najat Khan, Ph.D, as Chief R&D Officer, Chief Commercial Officer, and Board Member
Read More

Decoding Biology To Radically Improve Lives. Explore Our Story:

We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company.

It’s complex biology, decoded.

A synchronized combination of hardware, software and data used to industrialize drug discovery

DISCOVER OUR OPERATING SYSTEM ›

Reshaping the traditional drug discovery funnel

EXPLORE OUR APPROACH ›

One of the largest, broadest and deepest pipelines of any technology-enabled drug discovery company

SEE OUR PIPELINE ›

Collaborations with industry-leading companies addressing broad therapeutic areas

PARTNER WITH US ›

An incredible team with world-class talent, expertise and leadership

MEET OUR TEAM ›
© 2024 Recursion. All rights reserved.